SCHEMBL19968899

SCHEMBL19968899

CC1CCCN(c2cccc(S(=O)(=O)Nc3ccc(C(F)(F)F)c(-c4ccccc4CO)n3)n2)C1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TLR7 Q9NYK1 1/20 0.36
SCN1A P35498 3/20 0.36
SCN8A Q9UQD0 3/20 0.36
SCN9A Q15858 1/20 0.35
DPP4 P27487 2/20 0.35
ALDH1A1 P00352 2/20 0.35
MAPK1 P28482 2/20 0.35
RAB9A P51151 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
LMNA P02545 1/20 0.35
POLB P06746 1/20 0.35
MAPT P10636 1/20 0.35
KDM4E B2RXH2 1/20 0.35
SLC6A9 P48067 1/20 0.34
SCN5A Q14524 1/20 0.34
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
SCN10A Q9Y5Y9 2/20 0.33
TRPV1 Q8NER1 1/20 0.33
PIK3CD O00329 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19968901 0.94 SCN1A (0.35) TLR7SCN1ASCN8ASCN9ADPP4
SCHEMBL19968885 0.88 HSD11B1 (0.40) TLR7SCN1ASCN8ASCN9AALDH1A1
SCHEMBL19925422 0.85 ITGB2 (0.38) SCN1ASCN8ADPP4ALDH1A1POLB
SCHEMBL19925788 0.85 ITGB2 (0.38) SCN1ASCN8ADPP4ALDH1A1POLB
SCHEMBL19925424 0.85 ITGB2 (0.38) SCN1ASCN8ADPP4ALDH1A1POLB
SCHEMBL29464328 0.85 ITGB2 (0.38) SCN1ASCN8ADPP4ALDH1A1POLB
SCHEMBL29464387 0.85 ITGB2 (0.38) SCN1ASCN8ADPP4ALDH1A1POLB
SCHEMBL22323219 0.84 IDH1 (0.39)
SCHEMBL22323180 0.84 IDH1 (0.39)
SCHEMBL22323183 0.84 IDH1 (0.39)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180072673-A1 N-(pyridin-2-yl)pyridine-sulfonamide Derivatives and their Use in the Treatment of Disease NOVARTIS AG (CH) 2018-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180072673-A1 N-(pyridin-2-yl)pyridine-sulfonamide Derivatives and their Use in the Treatment of Disease CFTR, P2RY1, P2RX5 TLR7 584/4885SCN1A 32/4885SCN8A 450/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.